-
Mashup Score: 0Perceived Benefit or Burden of Research Participation and Withdrawal From Cancer Trials - 2 year(s) ago
This survey study analyzes the association of patients’ perceived benefits and burdens of research participation with retention in cancer clinical trials.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Medical Student Clinical Research Fellowship - 2 year(s) ago
MSKCC Radiation Oncology Medical Student Clinical Research Fellowship
Categories: Hem/Oncs, Latest HeadlinesTweet-
✍️ Now accepting applications for a year-long Medical Student Clinical Research Fellowship in #oncology, co-hosted @uwradonc w/ @JunMaoMD in #integrativemedicine @MSKCancerCenter. 🗓Due 12/31! For more info: https://t.co/nHW4q8mhlh #radonc #MedStudentTwitter @roecsg @RadOncPDs
-
-
Mashup Score: 0College Course Delivery Model and Psychological Distress During the COVID-19 Pandemic - 2 year(s) ago
This cross-sectional analysis uses national data from the American College Health Association–National College Health Assessment III data set to study the association between course delivery model and psychological distress among college students.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
💡More data that hybrid >> online only 📰 @JAMANetworkOpen: https://t.co/5vMrrmeGIw Cross-sectional study of 59k college students (61% online only, 35% mixed online/in-person) found online only ⬆️ psychological distress (b = 0.76 [99% CI, 0.64-0.88]; P < .001). @dsouzl @roecsg
-
-
Mashup Score: 0
: Guidelines for early-stage breast cancer allow for radiation therapy (RT) omission after breast conserving surgery among older women, though high utilization of RT persists. This study explored surgeon referral and the effect of a productivity-based bonus metric for radiation oncologists in an academic institution with centralized quality assurance review.
Source: Advances in Radiation OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
In a retrospective study across @MSK_RadOnc network, we evaluated use of RT for elderly ER+ early-stage #bcsm before/after implementing a productivity-based bonus metric and found *no change*. More on incentive design + central QA in #AdvancesRO 📰: https://t.co/fl9hIANmED https://t.co/kzlWcRA9Xb
-
-
Mashup Score: 0
PURPOSE On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the noninferiority external-beam partial breast irradiation (PBI) trial (ClinicalTrials.gov identifier: NCT00892814). We hypothesized that PBI was noninferior to WBI regarding breast induration….
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#bcsm #radonc DBCG RCT ⚖️ of WBI vs PBI (both 40Gy/15) 📰 in @JCO_ASCO (prev 👩🏫 @ESTRO_RT): https://t.co/m51lLSqI8P 3-yr induration: 9.7% (WBI) vs 5.1% (PBI), (p=.014) -->Difference pronounced in larger-breasted pts LRR at 7.6yrs f/u: 6 (WBI) vs 10 (PBI) events (p=0.28)
-
-
Mashup Score: 2A Meta-Analysis of Trials of Partial Breast Irradiation - 2 year(s) ago
Partial breast irradiation (PBI) is the delivery of radiation therapy (RT) limited to the tumor bed after breast conserving surgery. The results of recent trials of PBI compared with whole breast irradiation (WBI) have suggested conflicting results with respect to local control and toxicity. The purpose of this meta-analysis was to assess effectiveness of PBI and to compare the different…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Meta-analysis of aggregate data from >16k #bcsm pts tx w/ PBI vs WBI 📰 in @IJROBP: https://t.co/s4EEkyWSEb Findings similar to B39: 1⃣"WBI more effective than PBI, but effectiveness of PBI technique related; 2⃣"absolute diff btwn groups for IBTR <1%, supporting [use of PBI]"
-
-
Mashup Score: 0Mitigating acute chemotherapy-associated adverse events in patients with cancer - Nature Reviews Clinical Oncology - 2 year(s) ago
Either alone or in combination, chemotherapy remains the mainstay treatment for most human malignancies. This treatment modality is associated with a high burden of chemotherapy-associated adverse events (CAAEs) that greatly affect patients because of their considerable morbidity, mortality and costs. Kuderer et al. discuss the pathophysiology, management and risk factors of the most common acute…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice 📰 in @NatRevClinOncol on limiting chemo-related AEs: https://t.co/VdVWXPDW7s 👇Discussion with authors highlights several key points re ⬆️importance of treatment-related toxicity: https://t.co/dpcUqX4vfr https://t.co/I3Ar39YOOm
-
-
Mashup Score: 3
This Viewpoint discusses the advantages of having a dedicated metastatic disease radiation oncology program addressing the specific needs of patients with metastatic cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
👍The Metastatic Disease Service @MSK_RadOnc has both inpatient + outpatient components, develops clinical guidelines across cancer types which facilitates trials ⚖️ for both oligomet + palliative indications. More @JAMAOnc 📰: https://t.co/GYn0AH54LC @JYangMDPhD @CJTsaiMDPhD https://t.co/W5bMpIVQ9e
-
-
Mashup Score: 4
ISRCTN Number/Clinical trials.gov, ID: NCT03523351 . Registered on 14 May 2018.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@PBlanchardMD @piet_ost @_ShankarSiva @DrewMoghanaki @HenningWillers @PeterMacRadOnc @ASTRO_org @VedangMurthy @MikeChuongMD @MSKCancerCenter @JackWestMD @n8pennell 👍 With only 1/62 events in RT arm, it’s hard to say much re dose/fx, except even 8Gy/1 prob works (it was re-RT after 20Gy/5 for CRPC). Could look at dose vs OS if tumor debulking a viable mechanism, but seems unlikely. Link to ⚖️ protocol 📰: https://t.co/ltUR5nCn0M #ASTRO22
-
-
Mashup Score: 2Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers - 2 year(s) ago
This cross-sectional study reports parking fees at National Cancer Institute–designated cancer treatment centers to assess parking costs for the treatment duration of certain cancers.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@HenningWillers Hard to disagree with that! https://t.co/fRZi508w0a @JAMAOnc @fumikochino @AnnaLeeMDMPH
-
“For participants who reported benefits [of clinical ⚖️] as = or > than burdens, 13% withdrew. For those perceiving benefits as < than burdens, 33% withdrew (adjusted OR, 3.38; 95% CI, 1.13-10.14; P = .03).” 📰 @JAMANetworkOpen: https://t.co/3jLm9idbn6 @JunMaoMD @nick_verdini